Development and Regulatory Milestones. In partial consideration of the obligations imposed on REGENX and rights granted to PARTNER hereunder and under the Penn Sublicense Agreement, PARTNER shall pay to REGENX the following one-time payments within after the achievement of each of the following milestone events by or on behalf of the Parties, any of their Affiliates or any Sublicensee in activities under this Agreement during the Term with respect to the applicable Licensed Product for use in the Licensed Field, which shall be nonrefundable, non-creditable and fully earned upon the achievement of the applicable milestone event:
Development and Regulatory Milestones. As partial consideration for the exclusive rights and covenants granted by Poseida to Takeda pursuant to this Agreement, Takeda shall make non-refundable, non-creditable milestone payments (each, a “Development and Regulatory Milestone Payment”) to Poseida upon achievement of the milestones set forth below (each, a “Development and Regulatory Milestone”) on a Program-by-Program basis. Takeda will notify Poseida of the achievement of each Development and Regulatory Milestone no later than [……] after Takeda becoming aware of the achievement thereof. Thereafter, Poseida will provide Takeda with an invoice for the corresponding Development and Regulatory Milestone Payment, and Takeda will pay to Poseida such Development and Regulatory Milestone Payment no later than [……] after receipt by Takeda thereof.
In accordance with the terms and conditions of this Agreement, upon the achievement of each of the following milestones set forth below for Products developed by or on behalf of Licensee, its Affiliates, or its or their sublicensees (as applicable), the corresponding one-time milestone payment will be due to MSD, :
Development and Regulatory Milestones. Licensee shall pay [[AstraZeneca:Organization]] each of the following non-refundable, non-creditable milestone payments upon the first achievement of the corresponding Milestone Event as set forth below in accordance with Section 4.3.2:
Development and Regulatory Milestones. Subject to the remainder of this Section 6.4, Anteris shall pay to vTv the one-time, non-refundable, non-creditable milestone payments set forth in the table below upon the first achievement of the applicable milestone event by the first Licensed Product (whether by or on behalf of Anteris or its Affiliates or Sublicensees):
Tier 1 Programs; Optioned Tier 2 Programs. For each Tier 1 Program or Optioned Tier 2 Program, Roche shall pay Poseida each applicable non-creditable, non-refundable milestone payment set forth in the following table, in accordance with [Section 9.1.1], following the first achievement of the corresponding milestone event for such Tier 1 Program or Optioned Tier 2 Program, as applicable:
Development and Regulatory Milestones. With respect to each of the milestone events set forth in [Section 8.6.1 and 8.6.2]2], the Party that achieved such milestone event and with respect to each of the milestone events set forth in [Section 8.6.3], Roche shall inform the other Party or Poseida, as applicable, within following the achievement of such event. Roche shall pay Poseida the respective milestone payment payable pursuant to [Section 8.6] for achievement of such milestone event within of receipt of an undisputed invoice from Poseida with respect thereto after achievement of such milestone event.
Development and Regulatory Milestones. Ono shall notify [[Forty Seven:Organization]] in writing within after the first achievement by a Product of the applicable milestone event below (whether by Ono or its Affiliate or Sublicensee). Ono shall pay to [[Forty Seven:Organization]] the one-time, non-refundable, non-creditable payment for such milestone event set forth in the table below within of receipt by Ono of [[Forty Seven:Organization]]’s invoice for such milestone payment. For the avoidance of doubt, each of the following milestone payments shall be payable only once regardless of the number of times achieved by one or more Products.
Development Milestones. Within after the first achievement by any Product of each of the milestone events set forth in the table below, Licensee shall provide Verrica with written notice of such achievement. Within upon receipt from Verrica of an invoice and all Tax Documents for the relevant amount payable to Verrica under this Section 8.2, Licensee shall pay to Verrica the corresponding non-refundable, non-creditable milestone payment set forth in such table.
Development Milestones. Subject to the remainder of this Section 6.3 (Milestone Payments), on a Cardiomyopathy Milestone Target-by-Cardiomyopathy Milestone Target basis, [[MyoKardia:Organization]] will make each of the one-time milestone payments set forth in Table 6.3.3 (“Development Milestone Payments”) for the first achievement of each development milestone event set forth in Table 6.3.3 (“Development Milestone”) by the first Product directed against such Cardiomyopathy Milestone Target to achieve such event, pursuant to and in the amounts set forth in column (a), (b) or (c), depending upon whether such Cardiomyopathy Milestone Target is an Initial Cardiomyopathy Milestone Target (and, in such case, whether such Cardiomyopathy Milestone Target is the first Initial Cardiomyopathy Milestone Target to achieve the applicable Development Milestone) or a Secondary Cardiomyopathy Milestone Target. [[MyoKardia:Organization]] will notify Fulcrum of the achievement of a Development Milestone by [[MyoKardia:Organization]], its Affiliates or its Licensees, in writing within after such achievement. [[MyoKardia:Organization]] will pay Fulcrum the amount of the Development Milestone Payment corresponding to such Development Milestone within following the receipt of a corresponding invoice from Fulcrum. For the avoidance of doubt, each Development Milestone Payment will be payable only once with respect to a Cardiomyopathy Milestone Target, on the first achievement of the Development Milestone by the applicable Product directed against such Cardiomyopathy Milestone Target (if at all), notwithstanding the number of times one or more Products directed against such Cardiomyopathy Milestone Target may achieve such Development Milestone. For the further avoidance of doubt, in no event will the aggregate Development Milestone Payments payable by [[MyoKardia:Organization]] under this [Section 6.3.3] (Development Milestones) exceed: # with respect to the first achievement of each Development Milestone, collectively, by a Product directed against any Initial Cardiomyopathy Milestone Target; # except as set forth in the [foregoing clause (i)], on an Initial Cardiomyopathy Milestone Target-by-Initial Cardiomyopathy Milestone Target basis, for Products directed against an Initial Cardiomyopathy Milestone Target; and # on a Secondary Cardiomyopathy Milestone Target-by-Secondary Cardiomyopathy Milestone
AllDrafts is a cloud-based editor designed specifically for contracts. With automatic formatting, a massive clause library, smart redaction, and insanely easy templates, it’s a welcome change from Word.
And AllDrafts generates clean Word and PDF files from any draft.